AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06407583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ProMIO2.0 program
Description: ProMIO2.0 is a lifestyle intervention carried out by physiotherapy and dietetics. They guide and encourage the participants to achieve the following behavioral goals:~* moderate/intensive exercise (e.g. walking) for 150-300 minutes per week~* Muscle-strengthening exercises 2x a week~* Supplemented with balance and flexibility exercises~* 1.2 grams of protein per kilogram of body weight per day (\~25-30 grams of protein per meal, 4x/day) The combination of consultations, information sessions and on-site training at the physiotherapist should ensure that participants acquire the necessary knowledge, awareness and skills to adopt the health behavior in daily life. Materials such as posters, pedometers and videos are used for support.~The intervention is divided into 2 phases, which indicate the degree of professional guidance:~1. intensive guidance (month 0 - 3)~2. average guidance (months 4 - 6)
Study NCT06247618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: visor
Description: The treatment will have a duration of 4 weeks, with the execution of two sessions per week with the use of a viewer positioned on the head that allows users to navigate and interact in real time with a three-dimensional (3D) environment
Study NCT04481113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tosylate Monohydrate
Description: Given PO
Study NCT06339216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)
Description: Adebrelimab injection：Intravenous infusion, fixed dose 1200 mg, Day 1, Q3W. Until disease progression or intolerable toxicity occurs, the infusion should be administered over 30 to 60 minutes and over a maximum of 2 hours. When adalimumab is administered in combination with chemotherapy, Adebrelimab should be administered as an intravenous infusion first, followed by chemotherapy at least 30 minutes apart.~Apatinib mesylate：Administered orally, 250 mg/time, once daily, orally, half an hour after meals (the time of daily administration should be as same as possible), with warm boiled water, the missed dose of Apatinib during the course of treatment cannot be supplemented.~Paclitaxel for Injection(Albumin Bound)：Intravenous infusion, 250 mg/m2, day 1, Q3W, intravenous drip over 30 minutes.
Study NCT05056792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric strength training for 8 week
Description: Plyometric training for 8 week
Study NCT05056792 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric strength training for 8 week
Description: Plyometric training for 8 week
Study NCT05056792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional training
Description: Conventional training for 8 week
Study NCT05056792 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional training
Description: Conventional training for 8 week
Study NCT06287710 — intervention group
Intervention type: PROCEDURE
Intervention: Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).
Description: Study of diagnostic accuracy (non-interventional, prospective, monocentric). Fluid expansion will be delayed for a few minutes while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard test). This will allow to test the diagnostic performance of the index test for the prediction of fluid responsiveness.~The index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline (stroke volume, cardiac output, left ventricular ejection fraction), During a standardized abdominal compression (stroke volume),After the 10 to 20ml/kg fluid expansion prescribed by the physician in charge (cardiac output).
Study NCT04340258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cesium-131
Description: Cs-131 brachytherapy seed is a low-energy-gamma isotope that is contained in a titanium capsule. Dosing will be determined by a radiation oncologist study team member based on CT scan and intraoperative findings. The number of seeds and spacing will be outlined preoperatively based on the proposed square area of exposure in the resection bed. The plan is to deliver a total of 60-70Gy of radiation to the site.
Study NCT04340258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks. The drug will be infused through a peripheral line or an indwelling catheter. The first dose will be given 2 weeks prior to surgery. Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months. Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
Study NCT05510219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rapid infusion of obinutuzumab
Description: This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital. All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
Study NCT05519059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Pelareorep at 1.5×10\^10 TCID50, 3×10\^10 TCID50, 4.5×10\^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m\^2 on Day 1/8/15 per cycle
Study NCT06496022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Frail scale
Description: FRAIL scale for determining frailty (tired most of the time in the last 4 weeks; the presence of more than 5 diseases; difficulty or inability when climbing stairs and walking around the block; weight loss of more than 5% of the previous weight in the last 6 months).
Study NCT06496022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Barthel scale
Description: The Barthel scale is used to determine the degree of independence in daily life, the patient's household activity, the assessment of the quality of life and the necessary care.
Study NCT06496022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARC-F
Description: The SARC-F scale is used to identify muscle dysfunction (difficulty lifting things over 4.5 kg, walking around the room, difficulty climbing from a chair and up 10 steps, whether the respondent has fallen in the last year).
Study NCT06496022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FRAX
Description: FRAX Scale (Kazakhstan platform) fracture and osteoporosis risk assessment on the website https://frax.shef.ac.uk/FRAX/tool.aspx?country=72
Study NCT06496022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mini-Cog scale
Description: The Mini-Cog scale defines cognitive impairment (cognitive impairment - when scoring less than 3 points based on remembering three words and evaluating the task of drawing a clock).
Study NCT06496022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: dynamometry
Description: carpal dynamometry (sarcopenia is exhibited at values below 26 units for men and below 16 units for women).
Study NCT05252481 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Eight sessions of transcranial current direct stimulation
Study NCT05252481 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Eight sessions of transcranial current direct stimulation (sham)
Study NCT06016465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Two 4mg pills
Study NCT06016465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo pills
Study NCT05346549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High energy preload
Description: Tests the extent to which participants reduce their food intake at a meal following ingestion of a high energy preload drink.
Study NCT05346549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy preload
Description: Tests the amount participants eat at a meal following ingestion of a low energy preload drink
Study NCT05813587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meplazumab for injection
Description: Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
Study NCT05813587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study NCT06041464 — intervention group
Intervention type: OTHER
Intervention: cell culture
Description: isolation of cell culture
Study NCT05285020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alter G
Description: It is anti-gravity treadmill treatment on Alter G. They will start with a 30-50% body weight load during the first week that will be progressively increased to 50-70% during the second (5% more each day during the 10 sessions as far as possible).~The slope will be 0% and the speed 2-3km/h the first week and 3-4 km/h the second. Treatment will be performed during 15 minutes for two weeks (10 sessions).
Study NCT05285020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parallel bars and Scale
Description: It is a re-education of the gait at the parallel bars with a progressive load in scale controlled by the patient during 10 minutes for two weeks.
Study NCT05285020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parallel bars and Scale
Description: It is a re-education of the gait at the parallel bars with a progressive load in scale controlled by the patient during 10 minutes for two weeks.
Study NCT05285020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation protocol
Description: It is the hospital's standard protocol for that injuries once a day for two weeks.
Study NCT05285020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard rehabilitation protocol
Description: It is the hospital's standard protocol for that injuries once a day for two weeks.
Study NCT06451549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syndi recommender system for mental health apps
Description: Syndi is a mental health app recommendation system. It provides personalised suggestions of apps to help users self-manage their mental health based on a clinical assessment.
Study NCT04775498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face psychoeducation group
Description: All of the investigation centers participating in this study have a psychoeducation programme on bipolar disorders labeled and monitored by their Regional Health Agency. For this, he must respect the decree of January 14, 2015 relating to the specifications of therapeutic education programs for the patient. Patients will be receive by an investigator, for inclusion and baseline evaluation and at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
Study NCT04775498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIMPLe mobile application
Description: The experimental intervention consists of 12 months use SIMPLe smartphone application who has been developed by the Barcelona Institute of neuroscience. The purpose of this application is to deliver individualized psychoeducation messages to the patient's clinical condition. The psychoeducational messages correspond to the contents of the different modules and sessions carried out in face-to-face psychoeducation groups (Colomm \& Vieta ; 2015). Patients will be receive by an investigator for inclusion and baseline evaluation, at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
Study NCT05450640 — intervention group
Intervention type: OTHER
Intervention: satisfaction survey
Description: 1 eQuestionnaire per patient completed during study
Study NCT05027048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium chloride
Description: See arm description above
Study NCT05027048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: see arm description above
Study NCT05506514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water immersion
Description: Comparison of 3 different water temperatures
Study NCT05506514 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water immersion
Description: Comparison of 3 different water temperatures
Study NCT04960852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a single shade structurally colored universal resin composite
Description: Omnichroma is a single shade composite that is claimed to have blending effect with the tooth color, thus eliminate shade matching procedures during restorative treatment
Study NCT06424587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: : In addition to the routine practice of the clinic, the pediatric patients in this group listened to music through headphones for 20 minutes just before the procedure to reduce the child's anxiety and fear. The therapeutic effect of music was used. Before the study, children between the ages of 6 and 12 who were inpatients at the clinic were asked what music they most liked to listen to, what kind of music they liked, and what their favorite artists and songs were. The music was selected based on the children's answers. In addition, the researcher added children's songs by a musician named Banu Kanıbelli
Study NCT06230029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Music will be played through individual headphones (BOSE AE2®). The headphones give the impression of personalized music that only the patient can hear. Patients will have a mask over their eyes to limit visual aggression. The songs will be pre-recorded on a digital tablet (Samsung Galaxy®) allowing the broadcasting of music programs. Patients will have the choice to listen to a song according to their musical preferences among 16 different musical styles. The volume will be adapted to the level that suits the patient.
Study NCT06094101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine IPX
Description: Peptide vaccine is a combination of~1. class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~2. class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~3. control peptide derived from Survivin.~4. adjuvant: toll like receptor (TLR) 1/2 ligand XS15.
Study NCT05650346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Cervical Training
Description: The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.
Study NCT05650346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Cervical Training
Description: The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.
Study NCT05650346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep cervical training + Upper cervical mobilization group
Description: 1. the patient in supine crook lying with the neck in a neutral position.The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg~2. The therapist will cover the rear of the cervical part of the participant with his right hand for stabilization, and will place his thumb and index fingers on the atlas of the participant. To conduct the atlanto-occipital mobilization, the therapist will place his left hand at the right side of the participant and at the same time will place his fifth finger under the occipital area and will pull the participant's head toward his trunk.
Study NCT05650346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep cervical training + Upper thoracic mobilization group
Description: 1. The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.~2. The participants will be placed in the prone position and the therapist will stand facing the joint where the mobilization will be applied to improve the extension of the upper thoracic spine (T1-2).
Study NCT05189496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy
Description: hyperbaric oxygen therapy
Study NCT05691491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05691491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05691491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05691491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05691491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given orally (PO)
Study NCT05691491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Given PO
Study NCT01189734 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: laparoscopic common bile duct exploration
Study NCT01189734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy and intraoperative endoscopic sphincterotomy
Study NCT05061017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixatimod
Description: Pixatimod is an investigational drug that is being evaluated in studies involving melanoma, non-small cell lung cancer, and microsatellite stable colorectal cancer.
Study NCT05061017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, gastric carcinoma and gastroesophageal junction (GEJ) cancer
Study NCT05061017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (low dose)
Description: Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab